Time to Buy NantKwest, Inc. (NK) After The Completion of This Bullish Descending Triangle?

June 19, 2018 - By Marguerite Chambers

NantKwest, Inc. (NASDAQ:NK) Logo

The stock of NantKwest, Inc. (NK) formed a descending triangle with $3.07 target or 7.00 % above today’s $2.87 share price. The 7 months triangle pattern indicates low risk for the $224.11 million company. If the $3.07 price target is reached, the company will be worth $15.69 million more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

The stock decreased 5.90% or $0.18 during the last trading session, reaching $2.87. About 467,897 shares traded or 172.16% up from the average. NantKwest, Inc. (NASDAQ:NK) has declined 8.37% since June 19, 2017 and is downtrending. It has underperformed by 20.94% the S&P500.

Analysts await NantKwest, Inc. (NASDAQ:NK) to report earnings on August, 6. They expect $-0.38 EPS, down 31.03 % or $0.09 from last year’s $-0.29 per share. After $-0.35 actual EPS reported by NantKwest, Inc. for the previous quarter, Wall Street now forecasts 8.57 % negative EPS growth.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company has market cap of $224.11 million. The firm develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It currently has negative earnings. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: